For Immediate Release
Contact: Evita Almassi, email@example.com
Telephone: (202) 682-2640
National Women’s Health Network Applauds Approval of New Contraceptive
Washington, D.C. — Today the FDA approved Annovera. Annovera provides protection against pregnancy for up to one year. “We’re excited that there’s a new contraceptive option that is not only long-lasting, but can be controlled by the user. That’s an important advance,” stated Cynthia Pearson.
The vaginal contraceptive system, developed by the Population Council, utilizes a new progesterone derivative, Segesterone Acetate, in combination with ethinyl estradiol, a hormone that has been used in previous vaginal rings. While the NuvaRing is only effective for a month, the Population Council’s vaginal contraceptive system is designed to be effective for 12 months with monthly removal and reinsertion. This makes the device not only more affordable, but also better for the environment since less material is thrown away. Unlike other vaginal contraceptive systems, Annovera requires no refrigeration.
“Many people like long-lasting contraceptives, but no one likes being stuck with a contraceptive they want to stop using”, said Pearson. “IUDs and implants require clinicians for both insertion and removal. In contrast, Annovera is a long acting contraceptive that patients can both insert and remove themselves.”
“We’re pleased that the FDA followed the science and approved a new contraceptive option and we look forward to more decisions like this in the future. People are depending on the FDA to rely on evidence, not politics to make decisions about reproductive health drugs and devices,” added Pearson.
The National Women’s Health Network is supported by our members and by choice we do not accept financial support from drug companies or medical device manufacturers. We bring the voices, concerns and needs of women consumers to policy and regulatory tables.